An extended phase Ib study found a 19.0% objective response rate (ORR) in patients with heavy pretreatment HER2-positive breast cancer., and An individual with brain metastasis had a 7.5-month partial response (52). The gene discussed is ERBB2; the disease is breast carcinoma.